BioWorld

Feb. 7, 2011

The Dark Side of Demand: Scaling Up Biologics

Increased demand for a drug is a welcome outcome of gaining regulatory approval and successful marketing. But scaling up production of biologics isn't easy. Read More

Money Raised Year to Date

Antitrust Probe for Alexion? History Shows No Big Deal

Obesity Drug Strike-Out May Shift Focus Back to GLP-1s

Week in Review

Word on the Street

U.S. Public Offering Performance By Underwriter: Jan. 1 - Dec. 31, 2010

Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010

Lead Underwriter Performance on All U.S. Offerings: Jan. 1 - Dec. 31, 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Photo of scale with woman sitting on floor holding head and arms on knees

Rethinking anorexia: A disorder of mind and metabolism

BioWorld Science

Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...